ALK-Negative Lung Cancer Transformation to ALK-Positive After Chemotherapy
The acquisition of ALK positivity in initially ALK-negative NSCLC after chemotherapy progression is exceedingly rare, but has been documented in isolated case reports, making it a clinically relevant phenomenon that warrants repeat molecular testing at progression.
Frequency of Transformation
The transformation from ALK-negative to ALK-positive status after chemotherapy is not a common occurrence based on available evidence:
Case report evidence: A 2026 case report 1 documented a 52-year-old female with initially ALK-negative lung adenocarcinoma who developed detectable ALK fusion after progression on platinum-based chemotherapy combined with VEGF and PD-L1 inhibitors. This represents documented proof of concept but highlights the rarity of this phenomenon.
Metastatic progression data: A 2013 study 2 examining 67 primary NSCLCs and their metastases found ALK rearrangement in 7.5% of primary tumors versus 9.0% of metastases (P < 0.001), suggesting some acquisition during disease evolution. However, this study examined metastatic progression rather than chemotherapy-induced changes specifically.
No population-level data exists: The NCCN guidelines 3 recommend repeat molecular profiling at progression but do not cite specific rates of ALK conversion after chemotherapy, indicating this is not a well-characterized phenomenon at the population level.
Clinical Implications and Mechanism
The proposed mechanism involves selective pressure from chemotherapy enriching pre-existing ALK fusion-positive clones that were below detection threshold at initial diagnosis 1. This is distinct from de novo mutation acquisition.
Key clinical takeaway: While transformation is rare, the NCCN guidelines 3 explicitly recommend considering plasma and/or tissue-based broad molecular profiling at disease progression to identify genomic resistance mechanisms and guide subsequent therapy. This recommendation applies regardless of initial ALK status.
Practical Recommendations
Repeat molecular testing is warranted at progression in ALK-negative patients, particularly when:
- Initial testing was performed on limited tissue
- Clinical features suggest ALK-positive disease (younger age, never-smoker, adenocarcinoma histology)
- Disease progression pattern is atypical
Testing methodology: Both FISH and immunohistochemistry are acceptable for ALK detection 4, with IHC being a validated equivalent alternative to FISH.
Important Caveats
The evidence base consists primarily of case reports rather than systematic studies. The true frequency remains unknown but appears to be very low. The clinical significance is that it can happen, not that it commonly does—making blanket retesting of all ALK-negative patients impractical, but targeted retesting in select cases reasonable, especially when comprehensive next-generation sequencing is being performed for other resistance mechanisms.